dpp 4 inhibitors and glp 1 agonists together GLP-1 receptor DPP-4 Pathway, Pharmacodynamics The effect of DPP-4 inhibitors,
Description
GLP-1 Use and Lower Incidence The study included 111,646 overweight and obese women
Prescribing information: VICTOZA (liraglutide) injection, for subcutaneous use
A few months later the drug gained authorisation in Canada, the European Union, Japan and then Australia in 2019
for weight loss in the form of Wegovy in 2021
Patients with atrial arrhythmias had risk factors for occurrence and continuation of arrhythmias: they were significantly older, more often had obesity, a history of AF and LV hypertrophy and were current tobacco users
Sawicki T, Ruszkowska M, Danielewicz A, Niedwiedzka E, Arukowicz T, Przybyowicz KE
